Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial.

Frederick Raal,Nyda Fourie,Russell Scott,Dirk Blom, Matthys De Vries Basson,Meral Kayikcioglu, Kate Caldwell,David Kallend,Evan Stein

European heart journal（2023）

引用 0|浏览19

暂无评分

摘要

Lerodalcibep, a novel anti-PCSK9 small binding protein dosed monthly as an alternative to monoclonal antibodies, significantly reduced LDL-C in subjects with HeFH with a safety profile similar to placebo.

查看译文

关键词

Lerodalcibep, Low-density lipoprotein cholesterol, Familial hypercholesterolaemia

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要